Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway - Takeaways - MDSpire

Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway

  • By

  • Wujie Chen

  • Fajiang Qian

  • Fengtong Wang

  • Fuquan Yang

  • Yuqing Shen

  • Mingxia Ding

  • Yuan Liu

  • July 3, 2026

  • 0 min

Share

  • 1

    PCP4 downregulation promotes prostate cancer progression by activating the Ca2+/CAMKK2/AMPK/AR signaling axis.

  • 2

    The study identifies PCP4 as a potential therapeutic target and prognostic marker in castration-resistant prostate cancer.

  • 3

    Low PCP4 expression correlates with higher T stage, Gleason score, and shorter disease-free survival in prostate cancer patients.

  • 4

    PCP4 is a repressive target gene of AR, revealing a feedback loop that drives tumor progression in castration-resistant prostate cancer.

  • 5

    The study establishes a comprehensive research framework that enhances the rigor and reliability of findings in prostate cancer research.

Original Source(s)

Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway

  • by Wujie Chen, Fajiang Qian, Fengtong Wang, Fuquan Yang, Yuqing Shen, Mingxia Ding, Yuan Liu

  • July 3, 2026

Related Content

Development and validation of a blood biomarker risk prediction model for postmenopausal endometrioid endometrial cancer

Business-in-Brief: June 2026

This month’s analytical science business news: Merck’s Bio-Techne acquisition, plus major ASMS product launches

  • July 2, 2026

  • 5 min
Role of the frontal aslant tract in language preservation and recovery after surgery: a multicenter analysis of patients with left frontal glioma